Press Release – 11/21/2024

Leading community-based practice to utilize increased set of solid tumor applications

Boston, MA and Rolle, Switzerland, November 21, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research.

Tennessee Oncology started using SOPHiA GENETICS in early 2024, when it began to validate the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™ alongside the SOPHiA DDM™ Hereditary Cancer Solution. As the practice worked with SOPHiA GENETICS throughout the year, it experienced the benefits of utilizing the SOPHiA DDM™ Platform for its next generation sequencing (NGS) testing and today announced it will begin to validate the SOPHiA DDM™ RNAtarget Technology and the SOPHiA DDM™ for Comprehensive Genomic Profiling (CGP) application.

“In our time using SOPHiA DDM™, we have been impressed with the outstanding results and incredible support, allowing us to retain our samples in-house and stay abreast of changing guidelines. The addition of these new applications will help us gain a better understanding of what drives cancers down to a molecular level,” said Thomas Stricker, MD, PhD, Pathology Lab Director, Center for Molecular and Genomic Studies, Tennessee Oncology.

The laboratory at Tennessee Oncology will streamline multiple NGS tests within one end-to-end workflow, allowing for a faster turnaround time and consolidating testing to save sample material. By combining RNA sequencing, CGP, and liquid biopsy testing,SOPHiA DDM™ delivers a comprehensive molecular view of cancer, improving a broader understanding of cancer biology for research that can help to improve future clinical decision-making and treatment planning for complex cancer cases.

“We are excited to expand our support of Tennessee Oncology and its network of oncology practices that are driving the future of community-based cancer care, especially as they bring these sophisticated tests to often underserved communities,” said John Carey, Managing Director, NORAM, SOPHiA GENETICS. “By furthering their research and providing access to advanced cancer testing, Tennessee Oncology is innovating the cancer landscape and improving outcomes for patients in need.”

For more information on how labs can benefit from SOPHiA’s end-to-end workflows across a multitude of applications, visit SOPHiAGENETICS.com, or connect on LinkedIn.  For more information on Tennessee Oncology, visit tnoncology.com, or connect on LinkedIn.

---

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

About Tennessee Oncology:

Tennessee Oncology, one of the nation’s largest community-based cancer care practices, is home to one of the leading clinical trial networks in the country. Established 1976 in Nashville, Tennessee Oncology’s mission remains unchanged: To provide access to high-quality cancer care and the expertise of clinical research for all patients, at convenient locations within their community and close to their home. Our growing network of physicians and locations is based on this mission. For more information, visit www.tnoncology.com.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence. 

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Media Contact:

Kelly Katapodis

[email protected]

Source : Sophiagenetics